# Safety and Pharmacokinetic Study of Fixed Dose Combination of Zidovudine, Lamivudine, and Nevirapine in HIV-Infected Children in Thailand

> **NCT00672412** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 42 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** GPO-Vir Z30 tablet
- **DRUG:** Lamivudine
- **DRUG:** Nevirapine
- **DRUG:** Zidovudine

## Key facts

- **NCT ID:** NCT00672412
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10
- **Primary completion:** 2010-01
- **Final completion:** 2010-01
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2021-11-09

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00672412

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00672412, "Safety and Pharmacokinetic Study of Fixed Dose Combination of Zidovudine, Lamivudine, and Nevirapine in HIV-Infected Children in Thailand". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT00672412. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*